EMA Authorised: Icandra (previously Vildagliptin / metformin hydrochloride Novartis) (vildagliptin;metformin hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Icandra, a fixed-dose combination of vildagliptin and metformin hydrochloride, for Type 2 diabetes mellitus. The marketing authorization hold…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Icandra (vildagliptin/metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novartis Europharm Limited. Decision date: 04/12/2025